NCT05038839
Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors treatment 1 active_not_recruiting NCT05227326
AOH1996 for the Treatment of Refractory Solid Tumors No drug interventions treatment 1 recruiting NCT06357975
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) treatment 2 active_not_recruiting NCT06357988
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T) treatment 2 active_not_recruiting NCT06360575
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) treatment 2 active_not_recruiting NCT06620302
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma treatment 1 / 2 not_yet_recruiting NCT02465060
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) screening 2 active_not_recruiting NCT03210714
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT03213678
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT03213704
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT04294628
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer treatment 1 active_not_recruiting NCT04320888
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial treatment 2 active_not_recruiting NCT05286801
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors treatment 1 / 2 recruiting NCT02867592
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors treatment 2 active_not_recruiting NCT03155620
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) screening 2 recruiting NCT03213652
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) treatment 2 recruiting NCT03698994
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT04195555
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT04197713
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study treatment 1 active_not_recruiting NCT05554341
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial treatment 2 suspended NCT04851119
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors treatment 1 / 2 recruiting NCT04870944
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma No drug interventions treatment 1 / 2 recruiting NCT05053971
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas treatment 1 / 2 recruiting NCT06223542
Studying TAK-243 in Patients With Advanced Cancer treatment 1 recruiting NCT06303167
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) treatment 2 active_not_recruiting NCT06308822
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) treatment 2 active_not_recruiting NCT03366103
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors treatment 1 / 2 terminated NCT04901702
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma treatment 1 / 2 active_not_recruiting NCT04439279
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) treatment 2 active_not_recruiting NCT03253679
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification treatment 2 completed NCT04530487
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults treatment 2 terminated NCT01364051
Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies treatment 1 active_not_recruiting NCT03784677
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors treatment 1 completed NCT06385483
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A) treatment 2 active_not_recruiting NCT05490771
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F) treatment 2 active_not_recruiting NCT04439188
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) treatment 2 active_not_recruiting NCT02095132
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors treatment 1 / 2 completed NCT06390852
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) treatment 2 active_not_recruiting NCT00939770
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma treatment 1 / 2 completed NCT04119024
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors treatment 1 recruiting NCT06385496
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) treatment 2 active_not_recruiting NCT02304458
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas treatment 1 / 2 completed NCT01709435
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors treatment 1 completed NCT03420963
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors treatment 1 recruiting NCT06400225
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L) treatment 2 active_not_recruiting NCT05791448
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease No drug interventions treatment 1 recruiting NCT04500548
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study treatment 1 withdrawn NCT06390826
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) treatment 2 active_not_recruiting NCT03213665
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT02975882
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors treatment 1 active_not_recruiting NCT04439292
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) treatment 2 active_not_recruiting NCT02079740
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors treatment 1 / 2 active_not_recruiting NCT04233567
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations treatment 2 active_not_recruiting NCT04439201
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B) treatment 2 active_not_recruiting NCT02780804
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors treatment 1 completed NCT03878095
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors treatment 2 active_not_recruiting NCT04439214
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) treatment 2 completed NCT02808650
Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors treatment 1 completed NCT03537690
FID-007 in Treating Participants With Advanced Solid Tumors treatment 1 recruiting NCT02671890
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer treatment 1 active_not_recruiting NCT06400264
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) treatment 2 withdrawn NCT03065387
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation treatment 1 active_not_recruiting NCT06400251
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) treatment 2 active_not_recruiting NCT04439253
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) treatment 2 active_not_recruiting NCT03217747
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies treatment 1 / 2 active_not_recruiting NCT06320405
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors treatment 1 / 2 recruiting NCT04439305
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) treatment 2 withdrawn NCT05111561
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer treatment 1 suspended NCT03925428
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas treatment 1 withdrawn NCT05071209
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors treatment 1 / 2 active_not_recruiting NCT04439175
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I) treatment 2 active_not_recruiting NCT05455606
Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment No drug interventions health_services_research Not Available recruiting NCT04439149
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) treatment 2 active_not_recruiting NCT04439136
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) treatment 2 active_not_recruiting NCT04439318
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) treatment 2 active_not_recruiting NCT03756818
TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT01303341
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma treatment 1 active_not_recruiting NCT03323034
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma treatment 1 active_not_recruiting NCT03878524
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial treatment 1 terminated NCT03220035
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT06390839
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C) treatment 2 active_not_recruiting NCT03320330
Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors treatment 1 / 2 completed NCT04439357
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) treatment 2 active_not_recruiting NCT04439266
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F) treatment 2 active_not_recruiting NCT06390865
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) treatment 2 active_not_recruiting NCT03430882
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors treatment 1 completed NCT02595931
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 active_not_recruiting NCT04439331
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U) treatment 2 active_not_recruiting NCT04439227
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) treatment 2 active_not_recruiting NCT03213691
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) treatment 2 active_not_recruiting NCT04981691
Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors No drug interventions treatment 1 unknown_status NCT02323880
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas treatment 1 active_not_recruiting NCT02159989
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery treatment 1 completed NCT04439344
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) treatment 2 active_not_recruiting NCT04439240
Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) treatment 2 completed NCT03233204
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) treatment 2 completed NCT04266912
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors treatment 1 / 2 active_not_recruiting NCT02535312
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin treatment 1 / 2 active_not_recruiting NCT04439110
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q) treatment 2 active_not_recruiting NCT04439123
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y) treatment 2 active_not_recruiting NCT06400238
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H) treatment 2 active_not_recruiting NCT03205644
VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors treatment 1 / 2 not_yet_recruiting